Biologics for chronic rhinosinusitis with nasal polyps: Economics and ethics
| Autor: | Christine B. Franzese, Kristine A. Smith, Joshua M. Levy, Amber U Luong, Jean Kim, Elina Toskala, Lauren T. Roland, Sarah K. Wise, Alan Regenberg, Kent Lam |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Biological Products
medicine.medical_specialty Side effect Chronic rhinosinusitis business.industry Treatment options Disease Appropriate use medicine.disease Patient preference Nasal Polyps Otorhinolaryngology Chronic Disease Health care medicine Humans Immunology and Allergy Nasal polyps Sinusitis Intensive care medicine business Rhinitis |
| Zdroj: | International Forum of Allergy & Rhinology. 11:1524-1528 |
| ISSN: | 2042-6984 2042-6976 |
| DOI: | 10.1002/alr.22864 |
| Popis: | Biologics have recently been approved for use in chronic rhinosinusitis with nasal polyps patients. While effective in controlling disease on subjective and objective short-term outcome measures, limited data suggest that biologics have the potential to be used long term. The current wholesale acquisition costs for biologics are quite high. Widespread, prolonged use of these medications may create a large burden to our healthcare system. Cost-effectiveness analyses, particularly for specific patient cohorts, are needed to determine appropriate use of these medications. The ethics of patient preference of various treatment options, counseling regarding side effect profiles, and healthcare economics also need to be addressed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|